Acta Med. 2004, 47: 257-262

https://doi.org/10.14712/18059694.2018.101

Gains and Losses of HLA Class II (DR) and CD4 in Atypical Hyperplasia, Carcinoma in situ and Infiltrating Ductal Carcinoma of the Breast

Demetrio Tamiolakisa, Ioannis Venizelosb, Maria Lambropoulouc, Theodoros Jivannakisc, Evagelia Seliniotakia, Panagiotis Tsikourasd, Vasilios Limberisd, Angelos Tsalkidise, Nikolas Papadopoulose

aGeneral Hospital of Chania, Department of Cytology, Chania, Greece
bIppokration Hospital of Salonica, Department of Pathology, Greece
cGeneral Hospital of Drama, Department of Pathology, Greece
dDemocritus University of Thrace, Department of Obstetrics and Gynecology, Alexandroupolis, Greece
eDemocritus University of Thrace, Department of Histology – Embryology, Alexandroupolis, Greece

Received May 1, 2004
Accepted July 1, 2004

References

1. Bartek J, Petrek M, Vogtesek B et al. HLA-DR antigens on differentiating human mammary gland epithelium and breast tumors. Br J Cancer 1987; 56:727–33. <https://doi.org/10.1038/bjc.1987.278> <PubMed>
2. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Preavalence of benign, atypical and malignant breast lesions in populations at different risk for breast cancer: a forensic autopsy study. Cancer 1987; 60:2751–60. <https://doi.org/10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M>
3. Bernard D, Maurizis JC, Ruse F et al. Presence of HLA-D/DR antigens on the membrane of breast tumor cells. Clin Exp Immunol 1984; 56:215–21.
4. Brunner CA, Gokel JM, Riethmller G et al. Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favorable prognosis. Eur J Cancer 1991; 27:411–6. <https://doi.org/10.1016/0277-5379(91)90374-M>
5. Concha A, Esteban F, Cabrera T et al. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2:47–54.
6. Concha A, Cabrera T, Ruiz-Cabello P et al. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer 1991; 6(suppl):146–54. <https://doi.org/10.1002/ijc.2910470726>
7. Concha A, Ruiz-Cabello F, Cabrera T, Nogales F, Collado A, Garrido F. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Eur J Immunogenet 1995; 22(4):299–310. <https://doi.org/10.1111/j.1744-313X.1995.tb00246.x>
8. Connolly JL, Schnitt SJ. Benign breast disease: resolved and unresolved issues. Cancer 1993; 71:1187–9. <https://doi.org/10.1002/1097-0142(19930215)71:4<1187::AID-CNCR2820710402>3.0.CO;2-V>
9. Cordell JL, Falini B, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32:219–29. <https://doi.org/10.1177/32.2.6198355>
10. Dammrich J, Buchwald J, Papadopoulos T, Muller-Hermelink HK. Special subtypes of pulmonary adenocarcinomas indicated by different tumor cell HLA-expression and stromal infiltrates. Virchows Arch B Cell Pathol 1991; 61:9–18. <https://doi.org/10.1007/BF02890400>
11. Doyle A, Martin WJ, Funa K. Markedly decreased expression of class I histocompatibility antigens protein, and mRNA in human small cell lung cancer. J Exp Med 1985; 161:1135–51. <https://doi.org/10.1084/jem.161.5.1135> <PubMed>
12. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146–51. <https://doi.org/10.1056/NEJM198501173120303>
13. Dupont WD, Parl FF, Hartmann WH et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71:1258–68. <https://doi.org/10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I>
14. Esteban F, Concha A, Huelin C et al. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 1989; 43:436–42. <https://doi.org/10.1002/ijc.2910430316>
15. Feinmesser M, Sulkes A, Morgenstern S, Sulkes J, Stern S, Okon E. HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol 2000; 53(4):286–91. <https://doi.org/10.1136/jcp.53.4.286> <PubMed>
16. Ghosh AK, Moore M, Street AJ et al. Expression of HLA-D sub-region products on human colorectal carcinomas. Int J Cancer 1986; 38:459–64. <https://doi.org/10.1002/ijc.2910380402>
17. Godfrey SE: Is fibrocystic disease of the breast precancerous? Arch Pathol Lab Med 1986; 110(11):991.
18. Goodenow RS, Vogel JM, Linsk RL et al. Histocompatibility antigens on murine tumors. Science 1985; 230:777–83. <https://doi.org/10.1126/science.2997918>
19. Gourley C, Thornton C, Massie C et al. Is there a relationship between HLA type and prognostic factors in breast cancer? Anticancer Research 2003; 23:633–8.
20. Hämmerling G, Maschek U, Sturmhöfel K et al. Regulation and functional role of MHC expression on tumors. In: Melchers F, Albert ED, Von Boehmer AH et al, eds. Progress in immunology, vol 7. Berlin: Springer-Verlag, 1989:pp1071–8.
21. Holden CA, Sanderson AR, MucDonald DM. Absence of human leukocyte antigen molecules in skin tumors and some cutaneous appendages: evidence using monoclonal antibodies. J Am Acad Dermatol 1983; 9:567–71. <https://doi.org/10.1016/S0190-9622(83)70200-8>
22. Hurlimann J, Saraga P. Mononuclear cells infiltrating human mammary carcinomas: Immunohistochemical analysis with monoclonal antibodies. Int J Cancer 1985; 35:753–62. <https://doi.org/10.1002/ijc.2910350610>
23. Kamma H, Yazawa T, Ogata T, Horiguchi H, Iijima T. Expression of MHC class II antigens in human lung cancer cells. Virchows Arch B Cell Pathol 1991; 60: 407–12. <https://doi.org/10.1007/BF02899573>
24. Kaufman JF, Auffray C, Korman AJ et al. The class II molecules of the human and murine major histocompatibility complex. Cell 1984; 36:1–13. <https://doi.org/10.1016/0092-8674(84)90068-0>
25. Koretz K, Moldenhauer G, Majdic O et al. Correlation of HLA-D/Ii antigen expression in breast carcinoma with local lymphohistiocytic infiltration reveals considerable dysregulation in a subset of tumors. In J Cancer 1989; 44:816–23.
26. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta- 2–microglobulin on human neuroblastoma cell lines. J Immunol 1983; 130: 2471–8.
27. Lazaro B, Anderson A, Kajdacsy-Balla A, Hessner M. Antigenic characterisation of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem Molecul Morphol 2001; 9:234–41.
28. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992; 267:941–4. <https://doi.org/10.1001/jama.1992.03480070057030>
29. Lucin K, Iternicka Z, Jonjic N. Prognostic significance of T-cell infiltrates, expression of 2–microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1984; 190:1134–40. <https://doi.org/10.1016/S0344-0338(11)80439-5>
30. Müller C, Ziegler A, Müller C et al. Divergent expression of HLA-DC/MB, -DR and -SB region products on normal and pathological tissues as detected by monoclonal antibodies. Immunbiology 1985; 169:228–49. <https://doi.org/10.1016/S0171-2985(85)80036-X>
31. Moller P, Mattfeldt T, Gross C et al. Expression of HLA-A, -B, -C, -DR, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibroadenoma, adenoma and carcinoma of the breast. Am J Pathol 1989; 135: 73–83.
32. Natali PG, Giacomini P, Bigotti A et al. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 1983; 43:660–8.
33. Natali P, Bigotti A, Cavalieri R et al. Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. Hum Immunol 1986; 15:220–33. <https://doi.org/10.1016/0198-8859(86)90028-5>
34. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994; 173:371–9. <https://doi.org/10.1002/path.1711730413>
35. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 1982; 49:751–8. <https://doi.org/10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y>
36. Parazzini F, La Vecchia C, Franceschi S et al. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984; 120:115–22. <https://doi.org/10.1093/oxfordjournals.aje.a113860>
37. Perez M, Cabrera T, Lopez Nevot MA et al. Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. J Immunogenet 1986; 13:247–53. <https://doi.org/10.1111/j.1744-313X.1986.tb01108.x>
38. Redondo M, Concha A, Oldiviela R et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 1991; 51:4948–54.
39. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 1991; 15:209–21. <https://doi.org/10.1097/00000478-199103000-00001>
40. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380–4. <https://doi.org/10.1038/35077246>
41. Rubin JT, Elwood LJ, Rusenberg SA et al. Immunohistochemical correlates of response to recombinant interleukin-2–based immunotherapy in humans. Cancer Res 1989; 49:7086–92.
42. Schnitt SJ, Connolly JL, Tavassoli FA et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992; 16:1133–43. <https://doi.org/10.1097/00000478-199212000-00001>
43. Schrier PI, Bernards R, Vaessen RT et al. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 1983; 305:771–5. <https://doi.org/10.1038/305771a0>
44. Tsuda H, Hirohashi S, Higuchi K et al. Beta-2–microglobulin expression in relation to amplification of oncogenes and prognosis in breast carcinoma. Histopathology 1990; 16:600–2.
45. van Duinen SG, Ruiter DJ, Broecker EB et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48:1019–25.
46. Vogel J, Tanaka K, Hoekzema GS et al. Experimental strategies for modification of histocompatibility antigen in tumor cell. Cancer Metastasis Rev 1987; 6: 677–93. <https://doi.org/10.1007/BF00047474>
47. Weiss MA, Michael JG, Pesce AJ et al. Heterogeneity of 2–microglobulin in human breast carcinoma. Lab Invest 1981; 45:46–57.
48. Wintzer HO, Benzing M, von Kleist S. Lacking prognostic significance of 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer 1990; 62:289–95. <https://doi.org/10.1038/bjc.1990.280> <PubMed>
49. Zuk JA, Walker RA. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J Pathol 1987; 152:275–85. <https://doi.org/10.1002/path.1711520406>
50. Zuk JA, Walker RA. HLA class II sublocus expression in benign and malignant breast epithelium. J Pathol 1988; 155:301–9. <https://doi.org/10.1002/path.1711550405>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive